[go: up one dir, main page]

MXPA02007901A - Nodulacion de la formacion de hueso. - Google Patents

Nodulacion de la formacion de hueso.

Info

Publication number
MXPA02007901A
MXPA02007901A MXPA02007901A MXPA02007901A MXPA02007901A MX PA02007901 A MXPA02007901 A MX PA02007901A MX PA02007901 A MXPA02007901 A MX PA02007901A MX PA02007901 A MXPA02007901 A MX PA02007901A MX PA02007901 A MXPA02007901 A MX PA02007901A
Authority
MX
Mexico
Prior art keywords
bone
deposition
modulation
bone formation
activator
Prior art date
Application number
MXPA02007901A
Other languages
English (en)
Inventor
Karen Still
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of MXPA02007901A publication Critical patent/MXPA02007901A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describe el uso de un activador o ligando de un receptor activado por el proliferador de la peroxisoma, diferente a PPARy, o un derivado farmaceuticamente aceptable del activador o ligando, en la fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades del hueso, permite por primera vez, el anabolismo del hueso para aumentar la deposicion del hueso en condiciones que se beneficiarian de una deposicion aumentada del hueso. Tambien se facilita lo inverso, en donde hay la inhibicion y/o retardo de la deposicion del hueso.
MXPA02007901A 2000-02-15 2001-02-15 Nodulacion de la formacion de hueso. MXPA02007901A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003310.0A GB0003310D0 (en) 2000-02-15 2000-02-15 Bone formation
PCT/GB2001/000626 WO2001060355A1 (en) 2000-02-15 2001-02-15 Modulation of bone formation

Publications (1)

Publication Number Publication Date
MXPA02007901A true MXPA02007901A (es) 2004-09-10

Family

ID=9885521

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02007901A MXPA02007901A (es) 2000-02-15 2001-02-15 Nodulacion de la formacion de hueso.

Country Status (18)

Country Link
US (1) US20030139372A1 (es)
EP (1) EP1259233A1 (es)
JP (1) JP2003522787A (es)
KR (1) KR20020093808A (es)
CN (1) CN1430512A (es)
AU (1) AU3212101A (es)
BR (1) BR0108344A (es)
CA (1) CA2399810A1 (es)
CZ (1) CZ20022741A3 (es)
GB (1) GB0003310D0 (es)
HK (1) HK1049618A1 (es)
HU (1) HUP0204511A3 (es)
IL (1) IL151243A0 (es)
MX (1) MXPA02007901A (es)
NO (1) NO20023837L (es)
NZ (1) NZ520764A (es)
WO (1) WO2001060355A1 (es)
ZA (1) ZA200206318B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
AU2003257854A1 (en) * 2003-05-28 2005-01-21 Eisai R&D Management Co., Ltd Compositions and foods and drinks contiaing higher fatty acid derivative
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
PL1667964T3 (pl) * 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JP5016922B2 (ja) * 2003-09-19 2012-09-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物
WO2006126541A1 (ja) * 2005-05-27 2006-11-30 Shionogi & Co., Ltd. ビタミンｋ類含有医薬組成物
NO20053517L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av lipidsenkende midler
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
KR101417201B1 (ko) * 2008-01-02 2014-07-08 마린 바이오 씨오., 엘티디. 신경변성 질환을 치료하기 위한 조성물 및 방법
WO2010137944A1 (en) 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
CA2863183A1 (en) * 2012-02-15 2013-08-22 Basf Se Means and methods for assessing bone disorders
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
CN105327333B (zh) * 2015-10-30 2018-09-07 大连大学 可促进牙种植体周围成骨的口腔施用组合物及其制剂
CN110433156A (zh) * 2019-08-27 2019-11-12 成都元素平衡生物科技有限公司 芝麻素在成骨分化中的新应用
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
CN111789833A (zh) * 2020-08-31 2020-10-20 苏州大学 2-溴棕榈酸在制备防治骨丢失相关疾病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
JPH09295936A (ja) * 1996-04-30 1997-11-18 Kowa Techno Saac:Kk 人工透析患者の骨疾患治療用外用剤
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
EP1028724A1 (en) * 1997-11-10 2000-08-23 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
GB9824614D0 (en) * 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
BR0108344A (pt) 2003-03-11
NZ520764A (en) 2004-05-28
EP1259233A1 (en) 2002-11-27
NO20023837D0 (no) 2002-08-14
ZA200206318B (en) 2003-11-07
HUP0204511A3 (en) 2004-11-29
IL151243A0 (en) 2003-04-10
HK1049618A1 (zh) 2003-05-23
AU3212101A (en) 2001-08-27
CN1430512A (zh) 2003-07-16
KR20020093808A (ko) 2002-12-16
HUP0204511A2 (en) 2003-05-28
WO2001060355A1 (en) 2001-08-23
US20030139372A1 (en) 2003-07-24
NO20023837L (no) 2002-10-14
CZ20022741A3 (cs) 2003-03-12
JP2003522787A (ja) 2003-07-29
GB0003310D0 (en) 2000-04-05
CA2399810A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
MXPA02007901A (es) Nodulacion de la formacion de hueso.
EP1268412B8 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
NZ514574A (en) Novel method of treatment
MXPA03010285A (es) Derivados de furano y tiofeno que activan receptores activados por el proliferador de peroxisoma humana.
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
TW200420549A (en) Thiazole derivatives
PL345946A1 (en) Use of α1β1 integrin receptor inhibitors and tgf-β1 inhibitors in the treatment of kidney disease
NZ507203A (en) Use of dexmedetomidine for ICU sedation
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
NO954952D0 (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
GEP20043157B (en) Medicament Against Migraine Recurrence
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
BR0112874A (pt) Uso de fribratos para a preparação de um medicamento útil no tratamento de falha de coração congestiva
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
AU7419501A (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
SE9900438D0 (sv) The pharmacological use of certian cystine derivatives
UA38447A (uk) Спосіб лікування безбольової ішемії міокарда у хворих на артеріальну гіпертензію
NZ523676A (en) Use of cetyl myristate and cetyl palmitate to treat irritable bowel syndrome or irritable bowel disease